AFC
ATYR

Ares Financial Consulting’s aTyr Pharma ATYR Stock Holding History

Ares Financial Consulting’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Hold
2,000
– – ﹤0.01% 978
2026
Q1 		$1.7K Buy
+2,000
New +$1.69K ﹤0.01% 874

Other funds holding ATYR

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $1B AUM 33.02% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $3.16B AUM 29.04% 1-Year Est. Return
VR
Vision Retirement Ridgewood, New Jersey $414M AUM

Ares Financial Consulting's ATYR Position: Q2 2026 in Review

Ares Financial Consulting held its aTyr Pharma (ATYR) position steady in Q2 2026 at 2,000 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Ares Financial Consulting first reported a position in ATYR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.7K in Q1 2026. 23 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Ares Financial Consulting held 2,000 shares of aTyr Pharma worth $1.19K as of Q2 2026.
  • Ares Financial Consulting left its aTyr Pharma share count unchanged in Q2 2026.
  • aTyr Pharma made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #978 holding.
  • Ares Financial Consulting first reported a position in aTyr Pharma in Q1 2026 and has held it in 2 quarters since.
  • Ares Financial Consulting's aTyr Pharma position peaked at $1.7K in Q1 2026.
  • 23 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.